{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:36:42Z","timestamp":1790213802921,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NCI, USA","award":["UM1CA186690"],"award-info":[{"award-number":["UM1CA186690"]}]},{"name":"NCI, USA","award":["UM1CA186690"],"award-info":[{"award-number":["UM1CA186690"]}]},{"name":"NCI, USA","award":["UM1CA186690"],"award-info":[{"award-number":["UM1CA186690"]}]},{"name":"NCI, USA","award":["U24CA247643"],"award-info":[{"award-number":["U24CA247643"]}]},{"name":"NCI, USA","award":["U24CA247643"],"award-info":[{"award-number":["U24CA247643"]}]},{"name":"NCI, USA","award":["UM1CA186690"],"award-info":[{"award-number":["UM1CA186690"]}]},{"name":"NCI, USA","award":["UM1CA186690"],"award-info":[{"award-number":["UM1CA186690"]}]},{"name":"NCI, USA","award":["R01CA266172"],"award-info":[{"award-number":["R01CA266172"]}]},{"name":"NCI, USA","award":["U24CA247643"],"award-info":[{"award-number":["U24CA247643"]}]},{"name":"NCI, USA","award":["UM1CA186690"],"award-info":[{"award-number":["UM1CA186690"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-024-04745-6","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T09:48:18Z","timestamp":1737539298000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)"],"prefix":"10.1007","volume":"95","author":[{"given":"Anuradha","family":"Krishnamurthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diwakar","family":"Davar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan H.","family":"Moy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Christner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne L.","family":"Holleran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Deppas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Sclafani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Bakkenist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8978-9401","authenticated-orcid":false,"given":"Jan H.","family":"Beumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza C.","family":"Villaruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"issue":"8","key":"4745_CR1","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm2450","volume":"9","author":"KA Cimprich","year":"2008","unstructured":"Cimprich KA, Cortez D (2008) ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 9(8):616\u2013627. https:\/\/doi.org\/10.1038\/nrm2450","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"4745_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ctrv.2013.03.002","volume":"40","author":"E Fokas","year":"2014","unstructured":"Fokas E, Prevo R, Hammond EM, Brunner TB, McKenna WG, Muschel RJ (2014) Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat Rev 40(1):109\u2013117. https:\/\/doi.org\/10.1016\/j.ctrv.2013.03.002","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"4745_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2897","volume":"16","author":"MK Zeman","year":"2014","unstructured":"Zeman MK, Cimprich KA (2014) Causes and consequences of replication stress. Nat Cell Biol 16(1):2\u20139. https:\/\/doi.org\/10.1038\/ncb2897","journal-title":"Nat Cell Biol"},{"key":"4745_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","volume":"149","author":"AM Weber","year":"2015","unstructured":"Weber AM, Ryan AJ (2015) ATM and ATR as therapeutic targets in cancer. Pharmacol Ther 149:124\u2013138. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.12.001","journal-title":"Pharmacol Ther"},{"issue":"2","key":"4745_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","volume":"40","author":"A Ciccia","year":"2010","unstructured":"Ciccia A, Elledge SJ (2010) The DNA damage response: making it safe to play with knives. Mol Cell 40(2):179\u2013204. https:\/\/doi.org\/10.1016\/j.molcel.2010.09.019","journal-title":"Mol Cell"},{"issue":"4","key":"4745_CR6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1101\/gad.14.4.397","volume":"14","author":"EJ Brown","year":"2000","unstructured":"Brown EJ, Baltimore D (2000) ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev 14(4):397\u2013402","journal-title":"Genes Dev"},{"issue":"42","key":"4745_CR7","doi-asserted-by":"publisher","first-page":"44289","DOI":"10.18632\/oncotarget.6247","volume":"6","author":"FP Vendetti","year":"2015","unstructured":"Vendetti FP, Lau A, Schamus S, Conrads TP, O\u2019Connor MJ, Bakkenist CJ (2015) The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget 6(42):44289\u201344305. https:\/\/doi.org\/10.18632\/oncotarget.6247","journal-title":"Oncotarget"},{"issue":"36","key":"4745_CR8","doi-asserted-by":"publisher","first-page":"57714","DOI":"10.18632\/oncotarget.9757","volume":"7","author":"LC Villaruz","year":"2016","unstructured":"Villaruz LC, Jones H, Dacic S, Abberbock S, Kurland BF, Stabile LP, Siegfried JM, Conrads TP, Smith NR, O\u2019Connor MJ, Pierce AJ, Bakkenist CJ (2016) ATM protein is deficient in over 40% of lung adenocarcinomas. Oncotarget 7(36):57714\u201357725. https:\/\/doi.org\/10.18632\/oncotarget.9757","journal-title":"Oncotarget"},{"issue":"7","key":"4745_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.573","volume":"7","author":"PM Reaper","year":"2011","unstructured":"Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, Golec JM, Pollard JR (2011) Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 7(7):428\u2013430. https:\/\/doi.org\/10.1038\/nchembio.573","journal-title":"Nat Chem Biol"},{"issue":"9","key":"4745_CR10","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1172\/JCI96519","volume":"128","author":"FP Vendetti","year":"2018","unstructured":"Vendetti FP, Karukonda P, Clump DA, Teo T, Lalonde R, Nugent K, Ballew M, Kiesel BF, Beumer JH, Sarkar SN, Conrads TP, O\u2019Connor MJ, Ferris RL, Tran PT, Delgoffe GM, Bakkenist CJ (2018) ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J Clin Investig 128(9):3926\u20133940. https:\/\/doi.org\/10.1172\/JCI96519","journal-title":"J Clin Investig"},{"issue":"14","key":"4745_CR11","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1038\/s41388-018-0606-4","volume":"38","author":"C Wang","year":"2019","unstructured":"Wang C, Wang G, Feng X, Shepherd P, Zhang J, Tang M, Chen Z, Srivastava M, McLaughlin ME, Navone NM, Hart GT, Chen J (2019) Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition. Oncogene 38(14):2451\u20132463. https:\/\/doi.org\/10.1038\/s41388-018-0606-4","journal-title":"Oncogene"},{"issue":"9","key":"4745_CR12","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.190156","volume":"9","author":"N Hustedt","year":"2019","unstructured":"Hustedt N, Alvarez-Quilon A, McEwan A, Yuan JY, Cho T, Koob L, Hart T, Durocher D (2019) A consensus set of genetic vulnerabilities to ATR inhibition. Open Biol 9(9):190156. https:\/\/doi.org\/10.1098\/rsob.190156","journal-title":"Open Biol"},{"issue":"5","key":"4745_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125482","volume":"10","author":"KN Mohni","year":"2015","unstructured":"Mohni KN, Thompson PS, Luzwick JW, Glick GG, Pendleton CS, Lehmann BD, Pietenpol JA, Cortez D (2015) A synthetic lethal screen identifies DNA repair pathways that sensitize cancer cells to combined ATR inhibition and cisplatin treatments. PLoS ONE 10(5):e0125482. https:\/\/doi.org\/10.1371\/journal.pone.0125482","journal-title":"PLoS ONE"},{"issue":"12","key":"4745_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111371","volume":"40","author":"N Sugitani","year":"2022","unstructured":"Sugitani N, Vendetti FP, Cipriano AJ, Pandya P, Deppas JJ, Moiseeva TN, Schamus-Haynes S, Wang Y, Palmer D, Osmanbeyoglu HU, Bostwick A, Snyder NW, Gong YN, Aird KM, Delgoffe GM, Beumer JH, Bakkenist CJ (2022) Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-alpha\/beta expression. Cell Rep 40(12):111371. https:\/\/doi.org\/10.1016\/j.celrep.2022.111371","journal-title":"Cell Rep"},{"issue":"17","key":"4745_CR15","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1158\/1078-0432.CCR-21-0251","volume":"27","author":"ST Kim","year":"2021","unstructured":"Kim ST, Smith SA, Mortimer P, Loembe AB, Cho H, Kim KM, Smith C, Willis S, Irurzun-Arana I, Berges A, Hong JY, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kozarewa I, Pierce AJ, Dean E, Lee J (2021) Phase I study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer. Clin Cancer Res 27(17):4700\u20134709. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0251","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4745_CR16","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","volume":"125","author":"MR Middleton","year":"2021","unstructured":"Middleton MR, Dean E, Evans TRJ, Shapiro GI, Pollard J, Hendriks BS, Falk M, Diaz-Padilla I, Plummer R (2021) Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine +\/- cisplatin in patients with advanced solid tumours. Br J Cancer 125(4):510\u2013519. https:\/\/doi.org\/10.1038\/s41416-021-01405-x","journal-title":"Br J Cancer"},{"issue":"4","key":"4745_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41416-021-01406-w","volume":"125","author":"GI Shapiro","year":"2021","unstructured":"Shapiro GI, Wesolowski R, Devoe C, Lord S, Pollard J, Hendriks BS, Falk M, Diaz-Padilla I, Plummer R, Yap TA (2021) Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. Br J Cancer 125(4):520\u2013527. https:\/\/doi.org\/10.1038\/s41416-021-01406-w","journal-title":"Br J Cancer"},{"issue":"16","key":"4745_CR18","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","volume":"36","author":"A Thomas","year":"2018","unstructured":"Thomas A, Redon CE, Sciuto L, Padiernos E, Ji J, Lee MJ, Yuno A, Lee S, Zhang Y, Tran L, Yutzy W, Rajan A, Guha U, Chen H, Hassan R, Alewine CC, Szabo E, Bates SE, Kinders RJ, Steinberg SM, Doroshow JH, Aladjem MI, Trepel JB, Pommier Y (2018) Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors. J Clin Oncol 36(16):1594\u20131602. https:\/\/doi.org\/10.1200\/JCO.2017.76.6915","journal-title":"J Clin Oncol"},{"issue":"19","key":"4745_CR19","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","volume":"27","author":"TA Yap","year":"2021","unstructured":"Yap TA, Krebs MG, Postel-Vinay S, El-Khouiery A, Soria JC, Lopez J, Berges A, Cheung SYA, Irurzun-Arana I, Goldwin A, Felicetti B, Jones GN, Lau A, Frewer P, Pierce AJ, Clack G, Stephens C, Smith SA, Dean E, Hollingsworth SJ (2021) Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a phase I study. Clin Cancer Res 27(19):5213\u20135224. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1032","journal-title":"Clin Cancer Res"},{"issue":"27","key":"4745_CR20","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/JCO.19.02404","volume":"38","author":"TA Yap","year":"2020","unstructured":"Yap TA, O\u2019Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, Tunariu N, Perez-Lopez R, Rodrigues DN, Riisnaes R, Figueiredo I, Carreira S, Hare B, McDermott K, Khalique S, Williamson CT, Natrajan R, Pettitt SJ, Lord CJ, Banerji U, Pollard J, Lopez J, de Bono JS (2020) Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol Off J Am Soc Clin Oncol 38(27):3195\u20133204. https:\/\/doi.org\/10.1200\/JCO.19.02404","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4745_CR21","doi-asserted-by":"publisher","unstructured":"Stockton S, Shyr C, Cecchini M, Aljumaily R, Halfdanarson TR, Sonbol MB, Whisenant J, Ivy SP, LoRusso P, Das S, Gore S, Berlin J, Beumer JH, Heumann TR A phase I study of ATR inhibitor BAY1895344 (elimusertib) plus topotecan (ETCTN 10402): Results of dose escalation. In: 2024 ASCO Annual Meeting, Chicago, 2024. vol suppl 16. p 3076. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3076","DOI":"10.1200\/JCO.2024.42.16_suppl.3076"},{"key":"4745_CR22","doi-asserted-by":"publisher","unstructured":"Heumann TR, Stockton S, Cecchini M, Aljumaily R, Shyr C, Whisenant J, Starr JS, Dayyani F, Baranda JC, Trikalinos N, Ivy SP, LoRusso P, Das S, Gore S, Beumer JH, Berlin J A phase I study of irinotecan combined with BAY1895344 (ATR inhibitor) in advanced solid tumors: Results of ETCTN 10402 dose escalation. In: 2024 ASCO Annual Meeting, Chicago, 2024. vol suppl 16. p 3077. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3077","DOI":"10.1200\/JCO.2024.42.16_suppl.3077"},{"issue":"22","key":"4745_CR23","doi-asserted-by":"publisher","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","volume":"61","author":"KM Foote","year":"2018","unstructured":"Foote KM, Nissink JWM, McGuire T, Turner P, Guichard S, Yates JWT, Lau A, Blades K, Heathcote D, Odedra R, Wilkinson G, Wilson Z, Wood CM, Jewsbury PJ (2018) Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent. J Med Chem 61(22):9889\u20139907. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01187","journal-title":"J Med Chem"},{"issue":"14","key":"4745_CR24","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.18632\/oncotarget.2158","volume":"5","author":"AB Hall","year":"2014","unstructured":"Hall AB, Newsome D, Wang Y, Boucher DM, Eustace B, Gu Y, Hare B, Johnson MA, Milton S, Murphy CE, Takemoto D, Tolman C, Wood M, Charlton P, Charrier JD, Furey B, Golec J, Reaper PM, Pollard JR (2014) Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget 5(14):5674\u20135685. https:\/\/doi.org\/10.18632\/oncotarget.2158","journal-title":"Oncotarget"},{"issue":"1","key":"4745_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","volume":"19","author":"AM Wengner","year":"2020","unstructured":"Wengner AM, Siemeister G, Lucking U, Lefranc J, Wortmann L, Lienau P, Bader B, Bomer U, Moosmayer D, Eberspacher U, Golfier S, Schatz CA, Baumgart SJ, Haendler B, Lejeune P, Schlicker A, von Nussbaum F, Brands M, Ziegelbauer K, Mumberg D (2020) The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models. Mol Cancer Ther 19(1):26\u201338. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0019","journal-title":"Mol Cancer Ther"},{"key":"4745_CR26","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0615","author":"A Roulston","year":"2021","unstructured":"Roulston A, Zimmermann M, Papp R, Skeldon A, Pellerin C, Dumas-Berube E, Dumais V, Dorich S, Fader LD, Fournier S, Li L, Leclaire ME, Yin SY, Chefson A, Alam H, Yang W, Fugere-Desjardins C, Vignini-Hammond S, Skorey K, Mulani A, Rimkunas V, Veloso A, Hamel M, Stocco R, Mamane Y, Li Z, Young J, Zinda M, Black WC (2021) RP-3500: a novel, potent and selective ATR inhibitor that is effective in preclinical models as a monotherapy and in combination with PARP inhibitors. Mol Cancer Ther. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0615","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"4745_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris NRM, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS (2021) First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discov 11(1):80\u201391. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0868","journal-title":"Cancer Discov"},{"key":"4745_CR28","unstructured":"Administration FaD (2016) Fluorouracil injection. Food and Drug Administration,"},{"key":"4745_CR29","unstructured":"Administration FaD (2014) Irinotecan Intravenous Injection. Food and Drug Administration,"},{"issue":"2","key":"4745_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/jco.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andr\u00e9 T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, Gramont Ad (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2):229\u2013237. https:\/\/doi.org\/10.1200\/jco.2004.05.113","journal-title":"J Clin Oncol"},{"issue":"31","key":"4745_CR31","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1200\/jco.2013.54.1011","volume":"32","author":"R Guimbaud","year":"2014","unstructured":"Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, Andr\u00e9 T, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Boucher E, Rebischung C, Hammel P, Rougier P, Bedenne L, Bouch\u00e9 O (2014) Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive, F\u00e9d\u00e9ration Nationale des Centres de Lutte Contre le Cancer, and Groupe Coop\u00e9rateur Multidisciplinaire en Oncologie) study. J Clin Oncol 32(31):3520\u20133526. https:\/\/doi.org\/10.1200\/jco.2013.54.1011","journal-title":"J Clin Oncol"},{"issue":"11","key":"4745_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5455","volume":"36","author":"BF Kiesel","year":"2022","unstructured":"Kiesel BF, Parise RA, Krishnamurthy A, Gore S, Beumer JH (2022) Quantitation of the ataxia-telangiectasia-mutated and Rad3-related inhibitor elimusertib (BAY-1895344) in human plasma using LC-MS\/MS. Biomed Chromatogr 36(11):e5455. https:\/\/doi.org\/10.1002\/bmc.5455","journal-title":"Biomed Chromatogr"},{"issue":"5","key":"4745_CR33","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1097\/FTD.0b013e3181ec3bf5","volume":"32","author":"G Corona","year":"2010","unstructured":"Corona G, Elia C, Casetta B, Toffoli G (2010) Fast liquid chromatography-tandem mass spectrometry method for routine assessment of irinotecan metabolic phenotype. Ther Drug Monit 32(5):638\u2013646. https:\/\/doi.org\/10.1097\/FTD.0b013e3181ec3bf5","journal-title":"Ther Drug Monit"},{"issue":"2","key":"4745_CR34","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/rcm.3362","volume":"22","author":"JE Kosovec","year":"2008","unstructured":"Kosovec JE, Egorin MJ, Gjurich S, Beumer JH (2008) Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography\/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom RCM 22(2):224\u2013230. https:\/\/doi.org\/10.1002\/rcm.3362","journal-title":"Rapid Commun Mass Spectrom RCM"},{"issue":"1","key":"4745_CR35","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/s41467-024-45996-4","volume":"15","author":"EL Hardaker","year":"2024","unstructured":"Hardaker EL, Sanseviero E, Karmokar A, Taylor D, Milo M, Michaloglou C, Hughes A, Mai M, King M, Solanki A, Magiera L, Miragaia R, Kar G, Standifer N, Surace M, Gill S, Peter A, Talbot S, Tohumeken S, Fryer H, Mostafa A, Mulgrew K, Lam C, Hoffmann S, Sutton D, Carnevalli L, Calero-Nieto FJ, Jones GN, Pierce AJ, Wilson Z, Campbell D, Nyoni L, Martins CP, Baker T, Serrano de Almeida G, Ramlaoui Z, Bidar A, Phillips B, Boland J, Iyer S, Barrett JC, Loembe AB, Fuchs SY, Duvvuri U, Lou PJ, Nance MA, Gomez Roca CA, Cadogan E, Critichlow SE, Fawell S, Cobbold M, Dean E, Valge-Archer V, Lau A, Gabrilovich DI, Barry ST (2024) The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. Nat Commun 15(1):1700. https:\/\/doi.org\/10.1038\/s41467-024-45996-4","journal-title":"Nat Commun"},{"key":"4745_CR36","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.165615","author":"FP Vendetti","year":"2023","unstructured":"Vendetti FP, Pandya P, Clump DA, Schamus-Haynes S, Tavakoli M, diMayorca M, Islam NM, Chang J, Delgoffe GM, Beumer JH, Bakkenist CJ (2023) The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.165615","journal-title":"JCI Insight"},{"issue":"9209","key":"4745_CR37","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/s0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209):1041\u20131047. https:\/\/doi.org\/10.1016\/s0140-6736(00)02034-1","journal-title":"Lancet"},{"issue":"1","key":"4745_CR38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1634\/theoncologist.6-1-81","volume":"6","author":"LB Saltz","year":"2001","unstructured":"Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, Elfring GL, Locker PK, Miller LL (2001) Irinotecan plus fluorouracil\/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 6(1):81\u201391. https:\/\/doi.org\/10.1634\/theoncologist.6-1-81","journal-title":"Oncologist"},{"key":"4745_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04436-0","author":"BF Kiesel","year":"2022","unstructured":"Kiesel BF, Deppas JJ, Guo J, Parise RA, Clump DA, Bakkenist CJ, Beumer JH (2022) Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice. Cancer Chemother Pharmacol. https:\/\/doi.org\/10.1007\/s00280-022-04436-0","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"4745_CR40","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s00280-005-0166-5","volume":"58","author":"S Poujol","year":"2006","unstructured":"Poujol S, Bressolle F, Duffour J, Abderrahim AG, Astre C, Ychou M, Pinguet F (2006) Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. Cancer Chemother Pharmacol 58(3):292\u2013305. https:\/\/doi.org\/10.1007\/s00280-005-0166-5","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"4745_CR41","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/cpt.1124","volume":"105","author":"JH Beumer","year":"2019","unstructured":"Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Kim TW, Mathijssen RH, Zhang L, Arnold D, Muneoka K, Boku N, Joerger M (2019) Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology recommendations for 5-fluorouracil therapy. Clin Pharmacol Ther 105(3):598\u2013613. https:\/\/doi.org\/10.1002\/cpt.1124","journal-title":"Clin Pharmacol Ther"},{"key":"4745_CR42","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000324","author":"A Matthews","year":"2022","unstructured":"Matthews A, Pratz KW (2022) Optimizing outcomes in secondary AML. Hematol Am Soc Hematol Educ Program. https:\/\/doi.org\/10.1182\/hematology.2022000324","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"9","key":"4745_CR43","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc.2017.60","volume":"17","author":"ME McNerney","year":"2017","unstructured":"McNerney ME, Godley LA, Le Beau MM (2017) Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer 17(9):513\u2013527. https:\/\/doi.org\/10.1038\/nrc.2017.60","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"4745_CR44","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol Off J Am Soc Clin Oncol 33(3):244\u2013250. https:\/\/doi.org\/10.1200\/JCO.2014.56.2728","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4745_CR45","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175369","author":"MT Dillon","year":"2024","unstructured":"Dillon MT, Guevara J, Mohammed K, Patin EC, Smith SA, Dean E, Jones GN, Willis SE, Petrone M, Silva C, Thway K, Bunce C, Roxanis I, Nenclares P, Wilkins A, McLaughlin M, Jayme-Laiche A, Benafif S, Nintos G, Kwatra V, Grove L, Mansfield D, Proszek P, Martin P, Moore L, Swales KE, Banerji U, Saunders MP, Spicer J, Forster MD, Harrington KJ (2024) Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI175369","journal-title":"J Clin Invest"},{"issue":"6","key":"4745_CR46","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, Fontana E, Lee EK, Spigel DR, Hojgaard M, Lheureux S, Mettu NB, Carneiro BA, Carter L, Plummer R, Cote GM, Meric-Bernstam F, O\u2019Connell J, Schonhoft JD, Wainszelbaum M, Fretland AJ, Manley P, Xu Y, Ulanet D, Rimkunas V, Zinda M, Koehler M, Silverman IM, Reis-Filho JS, Rosen E (2023) Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat Med 29(6):1400\u20131411. https:\/\/doi.org\/10.1038\/s41591-023-02399-0","journal-title":"Nat Med"},{"issue":"2","key":"4745_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00280-021-04388-x","volume":"89","author":"BF Kiesel","year":"2022","unstructured":"Kiesel BF, Guo J, Parise RA, Venkataramanan R, Clump DA, Bakkenist CJ, Beumer JH (2022) Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice. Cancer Chemother Pharmacol 89(2):231\u2013242. https:\/\/doi.org\/10.1007\/s00280-021-04388-x","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04745-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04745-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04745-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T21:13:33Z","timestamp":1737580413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04745-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4745"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04745-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L.C.V. declares consulting with Astrazeneca, EMD Serono, Sanofi, Daiichi Sankyo, Gilead, Jazz, Johnson and Johnson, Takeda, BMS, and Bayer. D.D. declares the following: Grants\/Research Support (institutional): Arcus, Immunocore, Merck, Regeneron Pharmaceuticals Inc., Tesaro\/GSK; Consultant: ACM Bio, Ascendis, Castle, Clinical Care Options (CCO), Gerson Lehrman Group (GLG), Immunitas, Medical Learning Group (MLG), Replimmune, Trisalus, Xilio Therapeutics; CE Speakers\u2019 Bureau: Castle Biosciences. Steering Committee\/DSMC: Replimmune, Immunocore; Stockholder: Zola. R.H.M. declares consulting\/advisory board with Nimbus Therapeutics, IDEAYA Biosciences, Puretech Health; research funding (institutional) from Repare Therapeutics, Nimbus Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This was an NCI, CTEP sponsored, multicenter trial performed at four NCI-designated cancer centers, approved by the respective institutional review boards and ethics committees, under the NCI CIRB as the IRB of record. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This trial was registered under ClinicalTrials.gov Identifier: NCT04535401.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"27"}}